Optimind Pharma Corp.
OMND
CNSX
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 26.42% | -34.33% | 115.25% | 17.48% | -1.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 26.42% | -34.33% | 115.25% | 17.48% | -1.03% |
| Cost of Revenue | 69.62% | -13.13% | -14.77% | 405.56% | -18.56% |
| Gross Profit | -4.39% | -44.78% | 496.67% | -19.68% | 16.33% |
| SG&A Expenses | 51.83% | -79.45% | -76.82% | -74.56% | -78.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.26% | -71.89% | -70.13% | -67.44% | -72.62% |
| Operating Income | -183.67% | 91.73% | 101.43% | 84.81% | 92.88% |
| Income Before Tax | -210.61% | 86.90% | 99.72% | 96.48% | 91.37% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -210.61% | 86.90% | 99.72% | 96.44% | 91.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -210.61% | 86.90% | 99.72% | 96.44% | 91.37% |
| EBIT | -183.67% | 91.73% | 101.43% | 84.81% | 92.88% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -100.00% | 83.33% | 100.00% | 96.08% | 87.50% |
| Normalized Basic EPS | -- | 100.00% | 100.00% | 93.33% | 100.00% |
| EPS Diluted | -100.00% | 83.33% | 100.00% | 96.08% | 87.50% |
| Normalized Diluted EPS | -- | 100.00% | 100.00% | 93.33% | 100.00% |
| Average Basic Shares Outstanding | -6.05% | -5.56% | -10.42% | 5.69% | 11.92% |
| Average Diluted Shares Outstanding | -6.05% | -5.56% | -10.42% | 5.69% | 11.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |